Ariel Jones

GU Oncology Now

A study evaluated the efficacy of a cancer peptide vaccine plus pembrolizumab for locally advanced or metastatic urothelial carcinoma (UC). The results were presented during the 2021 ASCO Annual Meeting.&ldquo;TAS0313 is a cancer vaccine cocktail comprising three long peptides with a total of 12 cytotoxic T lymphocyte epitope peptides,&rdquo; the researchers explained in their abstract.The phase I/II study included patients diagnosed with UC with at least one of the following HLA types: HLA-A*02:01, -A*02:06, -A*02:07, -A*11:01, -A*24:02, -A*31:01, or -A*33:03.Cohort C1 included patients who received platinum-based chemotherapy and were na&iuml;ve to immune checkpoint inhibitors (ICI), while cohort C2 included patients who progressed while on pembrolizumab. Patients received 21-day cycles of TAS0313 9 mg subcutaneously on days 1, 8, and 15 of cycles 1 and 2 and day 1 of cycle 3 or later, while pembrolizumab (200 mg) was intravenously administered on day 1 of cycle 1 or later until disease progression or unacceptable toxicity.As of September 10, 2020, 36 patients in C1 and 10 in C2 had received the combination therapy. Median respective follow-up durations were 6.47 months and 6.95 months, and median treatment durations were 4.86 months and 2.56 months.The overall response (OR) rate in C1 was 33.3%, and disease control rate (DCR) was 66.7%. Median progression-free survival was 5 months, median overall survival (OS) was not yet reached, and one-year OS rate was 74.3%. In C2, the best OR was stable disease, achieved by half of the cohort, for a 50% DCR. Both groups had IgG level increases following treatment.The researchers said in their conclusion that &ldquo;a large-scale randomized study is needed to clarify the benefits of TAS0313 combined with ICI in ICI-na&iuml;ve pts.&rdquo;

TAS0313 Plus Pembrolizumab in Urothelial Carcinoma

American Society of Clinical Oncology 2021 Annual Meeting

ASCO 2021

A study evaluated the efficacy of a cancer peptide vaccine plus pembrolizumab for locally advanced or metastatic urothelial carcinoma.

About Us

Contributors and Partners

Editorial Policy

Advertising

eNewsletters

Calendar

Contact Us

Contribute

MashupMD

Cancer Nursing Today

Urban Health Today

Blood Cancers Today

DocWire News

Knowledge Hubs

Conference Coverage

Roundtables

The Uromigos

Uromigos Live 2024

AUC3

Localized

mHSPC/mCSPC

CRPC

Diagnostics

Prostate Cancer

Localized Renal Cell Carcinoma

Advanced Renal Cell Carcinoma

nccRCC

Renal Cell Carcinoma

Non-Muscle Invasive Urothelial Carcinoma

Muscle Invasive Urothelial Carcinoma

Advanced Urothelial Carcinoma

Upper Tract Urothelial Carcinoma

Urothelial Carcinoma

Testicular, Penile, and Rare Cancers

Video Insights

Advancements in Oncology

The Oncology Brothers

Expert Interviews

Journal

Subscribe